Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rapid dFLC Response Predict Complete Hematologica Response in Systemic AL Amyloidosis Patients Treated With Daratumumab-based Regimen

NCT06627309 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT06627309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06627309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rapid dFLC Response Predict Complete Hematologica Response in Systemic AL Amyloidosis Patients Treated With Daratumumab-based Regimen
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Recruiting
Start date
October 26, 2024
Completion date
December 31, 2026
Enrollment
50 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

systemic al amyloidosis